December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
From ImmunoGen, Inc.
Via Business Wire
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options... 
Via FinancialNewsMedia
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ImmunoGen, Inc.
Via Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... 
Via Benzinga
Topics Intellectual Property
10 Biggest Price Target Changes For Wednesday
Morgan Stanley boosted Zscaler, Inc. (NASDAQ: ZS) price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading. Citigroup boosted Applied... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of ADP, Manufacturing Data
Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording gains in the previous session. Investors are awaiting earnings results from G-... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Cumberland (NASDAQ:CPIX) stock... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lannett (NYSE:LCI) shares rose 11.61... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland... 
Via Benzinga
Why ImmunoGen Stock Soared Today
The cancer-fighting specialist's new antibody treatment could be a gamechanger. 
Via The Motley Fool
ImmunoGen Announces Proposed Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.44% to 34,628.69 while the NASDAQ fell 1.34% to 15,571.16. The S&P also fell, dropping 1.36% to 4,592.03. The U.S. has... 
Via Benzinga
Topics Stocks
These 2 Nasdaq Biotechs Are Bucking the Market Downtrend
Wall Street is having a bad day, but shareholders in these companies are celebrating. 
Via The Motley Fool
Topics Stocks
Mid-Day Market Update: Barnes & Noble Education Drops Following Q2 Results; Cumberland Pharmaceuticals Shares Jump
Midway through trading Tuesday, the Dow traded down 0.88% to 34,827.81 while the NASDAQ fell 0.78% to 15,659.31. The S&P also fell, dropping 0.3832% to 4,616.53. The U.... 
Via Benzinga
Topics Stocks
35 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an... 
Via Benzinga
ImmunoGen Shares Rally After Ovarian Cancer Trial Meets Primary Endpoint Goal
ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab... 
Via Benzinga
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Cumberland (NASDAQ:CPIX) shares rose 91.81% to $4.22 during Tuesday's pre-market session. The company's market cap stands at $62.4 million. First Wave... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're starting off Tuesday with a breakdown of the biggest pre-market stock movers you need to know about! 
Via InvestorPlace
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
From ImmunoGen Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.